Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 43

1.

Applying the IWG research criteria in clinical practice: feasibility and ethical issues.

Molinuevo JL, Rami L.

Med Clin North Am. 2013 May;97(3):477-84. doi: 10.1016/j.mcna.2012.12.018. Epub 2013 Feb 1. Review.

PMID:
23642582
2.

International Work Group criteria for the diagnosis of Alzheimer disease.

Cummings JL, Dubois B, Molinuevo JL, Scheltens P.

Med Clin North Am. 2013 May;97(3):363-8. doi: 10.1016/j.mcna.2013.01.001. Epub 2013 Feb 16.

PMID:
23642575
3.

Could clinical profile influence CSF biomarkers in early-onset Alzheimer disease?

Koric L, Felician O, Guedj E, Hubert AM, Mancini J, Boucraut J, Ceccaldi M.

Alzheimer Dis Assoc Disord. 2010 Jul-Sep;24(3):278-83. doi: 10.1097/WAD.0b013e3181d712d9.

PMID:
20473135
4.

Assessment of cerebrospinal fluid (CSF) beta-amyloid (1-42), phosphorylated tau (ptau-181) and total Tau protein in patients with Alzheimer's disease (AD) and other dementia at Siriraj Hospital, Thailand.

Thaweepoksomboon J, Senanarong V, Poungvarin N, Chakorn T, Siwasariyanon N, Washirutmangkur L, Udompunthuruk S.

J Med Assoc Thai. 2011 Feb;94 Suppl 1:S77-83.

PMID:
21721431
5.

Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice.

Andreasen N, Minthon L, Davidsson P, Vanmechelen E, Vanderstichele H, Winblad B, Blennow K.

Arch Neurol. 2001 Mar;58(3):373-9.

PMID:
11255440
6.

The role of CSF biomarkers in the diagnostic work-up of mixed vascular-degenerative dementia.

Engelborghs S, Le Bastard N.

J Neurol Sci. 2012 Nov 15;322(1-2):197-9. doi: 10.1016/j.jns.2012.08.003. Epub 2012 Sep 2.

PMID:
22947896
7.

Evaluation of CSF biomarkers as predictors of Alzheimer's disease: a clinical follow-up study of 4.7 years.

Hertze J, Minthon L, Zetterberg H, Vanmechelen E, Blennow K, Hansson O.

J Alzheimers Dis. 2010;21(4):1119-28.

PMID:
21504133
8.

[A new approach to the Alzheimer's disease diagnosis with biomarkers: description of the AD-CSF-Index].

Molinuevo JL, Gispert JD, Pujol J, Rojas S, Lladó A, Balasa M, Antonell A, Sánchez-Valle R, Rami L.

Rev Neurol. 2012 May 1;54(9):513-22. Spanish.

9.

Added diagnostic value of CSF biomarkers in differential dementia diagnosis.

Le Bastard N, Martin JJ, Vanmechelen E, Vanderstichele H, De Deyn PP, Engelborghs S.

Neurobiol Aging. 2010 Nov;31(11):1867-76. doi: 10.1016/j.neurobiolaging.2008.10.017. Epub 2009 Jan 15.

PMID:
19150153
10.

CSF biomarkers for Alzheimer's Disease: levels of beta-amyloid, tau, phosphorylated tau relate to clinical symptoms and survival.

Wallin AK, Blennow K, Andreasen N, Minthon L.

Dement Geriatr Cogn Disord. 2006;21(3):131-8. Epub 2006 Jan 2.

PMID:
16391474
11.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
13.

Tau protein, Abeta42 and S-100B protein in cerebrospinal fluid of patients with dementia with Lewy bodies.

Mollenhauer B, Cepek L, Bibl M, Wiltfang J, Schulz-Schaeffer WJ, Ciesielczyk B, Neumann M, Steinacker P, Kretzschmar HA, Poser S, Trenkwalder C, Otto M.

Dement Geriatr Cogn Disord. 2005;19(2-3):164-70. Epub 2005 Jan 5.

PMID:
15637452
14.

[Biomarkers for Alzheimer's disease: after Alzheimer's disease neuroimaging initiative studies].

Shoji M.

Brain Nerve. 2012 May;64(5):497-504. Review. Japanese.

PMID:
22570063
15.
16.

Diagnostic impact of CSF biomarkers in a local hospital memory clinic.

Kester MI, Boelaarts L, Bouwman FH, Vogels RL, Groot ER, van Elk EJ, Blankenstein MA, van der Flier WM, Scheltens P.

Dement Geriatr Cogn Disord. 2010;29(6):491-7. doi: 10.1159/000313534. Epub 2010 Jun 3.

PMID:
20523047
17.
18.

[The role of CSF markers in the early diagnosis of Alzheimer's disease].

Vos SJ, Visser PJ, Verhey FR.

Tijdschr Psychiatr. 2011;53(9):647-53. Dutch.

19.

High cerebrospinal fluid tau and low amyloid beta42 levels in the clinical diagnosis of Alzheimer disease and relation to apolipoprotein E genotype.

Galasko D, Chang L, Motter R, Clark CM, Kaye J, Knopman D, Thomas R, Kholodenko D, Schenk D, Lieberburg I, Miller B, Green R, Basherad R, Kertiles L, Boss MA, Seubert P.

Arch Neurol. 1998 Jul;55(7):937-45.

PMID:
9678311
20.

Episodic memory and speed/attention deficits are associated with Alzheimer-typical CSF abnormalities in MCI.

Nordlund A, Rolstad S, Klang O, Lind K, Pedersen M, Blennow K, Edman A, Hansen S, Wallin A.

J Int Neuropsychol Soc. 2008 Jul;14(4):582-90. doi: 10.1017/S135561770808079X.

PMID:
18577287

Supplemental Content

Support Center